RecruitingNot ApplicableNCT04919980

TVMR With the INNOVALVE System Trial - Early Feasibility Study


Sponsor

Edwards Lifesciences

Enrollment

65 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Study to evaluate the safety and performance of the INNOVALVE system


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Clinically significant, symptomatic mitral regurgitation
  • High risk for open-heart surgery
  • Meets anatomical criteria

Exclusion Criteria3

  • Unsuitable anatomy
  • Patient is inoperable
  • EF<25%

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEINNOVALVE system

INNOVALVE system


Locations(17)

Cedars-Sinai

Los Angeles, California, United States

Naples Comprehensive Health

Naples, Florida, United States

Piedmont Heart Institute

Atlanta, Georgia, United States

Northwestern

Chicago, Illinois, United States

University of Michigan Hospital and Health Systems

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Morristown Medical Center

Morristown, New Jersey, United States

Northwell Health

Manhasset, New York, United States

Cornell

New York, New York, United States

NewYork-Presbyterian / Columbia University

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

OhioHealth Research Institute

Columbus, Ohio, United States

Oregon Health & Science Universtiy

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Ascension Saint Thomas

Nashville, Tennessee, United States

Swedish Medical Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04919980


Related Trials